Fundamental Analysis of CLEARSIDE BIOMEDICAL INC(NASDAQ:CLSD) stock

Fundamental Rating

Taking everything into account, CLSD scores 3 out of 10 in our fundamental rating. CLSD was compared to 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of CLSD have multiple concerns. CLSD shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

CLSD had negative earnings in the past year.

CLSD had a negative operating cash flow in the past year.

In the past 5 years CLSD reported 4 times negative net income.

CLSD had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -95.51%, CLSD is doing worse than 81.03% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-95.51%
ROE	N/A
ROIC	N/A

ROA(3y)-52.95%

ROA(5y)-73.6%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of CLSD (95.70%) is better than 96.92% of its industry peers.

CLSD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	95.7%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CLSD does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, CLSD has more shares outstanding

CLSD has more shares outstanding than it did 5 years ago.

There is no outstanding debt for CLSD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -13.42, we must say that CLSD is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of CLSD (-13.42) is worse than 78.97% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-13.42

ROIC/WACCN/A

WACC9.31%

2.3 Liquidity

CLSD has a Current Ratio of 4.42. This indicates that CLSD is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 4.42, CLSD is in the better half of the industry, outperforming 62.05% of the companies in the same industry.

CLSD has a Quick Ratio of 4.42. This indicates that CLSD is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of CLSD (4.42) is better than 63.08% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	4.42
Quick Ratio	4.42

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 3.64% over the past year.

CLSD shows a strong growth in Revenue. In the last year, the Revenue has grown by 518.42%.

Measured over the past years, CLSD shows a very strong growth in Revenue. The Revenue has been growing by 207.34% on average per year.

EPS 1Y (TTM)3.64%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q50%

Revenue 1Y (TTM)518.42%

Revenue growth 3Y1.4%

Revenue growth 5Y207.34%

Revenue growth Q2Q1822.73%

3.2 Future

The Earnings Per Share is expected to grow by 32.09% on average over the next years. This is a very strong growth

Based on estimates for the next years, CLSD will show a very strong growth in Revenue. The Revenue will grow by 86.49% on average per year.

EPS Next Y-2.64%

EPS Next 2Y-4%

EPS Next 3Y-6.88%

EPS Next 5Y32.09%

Revenue Next Year-62.65%

Revenue Next 2Y10.68%

Revenue Next 3Y51.75%

Revenue Next 5Y86.49%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CLSD. In the last year negative earnings were reported.

Also next year CLSD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as CLSD's earnings are expected to decrease with -6.88% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-4%

EPS Next 3Y-6.88%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CLSD!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CLEARSIDE BIOMEDICAL INC

NASDAQ:CLSD (4/26/2024, 7:00:00 PM)

After market: 1.31 -0.03 (-2.24%)

1.34

+0.08 (+6.35%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap100.12M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-95.51%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	95.7%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.24

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	4.42
Quick Ratio	4.42
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)3.64%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-2.64%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)518.42%

Revenue growth 3Y1.4%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

CLEARSIDE BIOMEDICAL INC (CLSD)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens